Skip to main content

WHIM Syndrome

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

X4 Pharmaceuticals
2 programs
X4P-001PHASE_21 trial
MavorixaforPHASE_31 trial
Active Trials
NCT03005327Completed8Est. Jun 2022
NCT03995108Active Not Recruiting31Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
X4 PharmaceuticalsMavorixafor
X4 PharmaceuticalsX4P-001

Clinical Trials (2)

Total enrollment: 39 patients across 2 trials

NCT03995108X4 PharmaceuticalsMavorixafor

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Start: Oct 2019Est. completion: Dec 202531 patients
Phase 3Active Not Recruiting
NCT03005327X4 PharmaceuticalsX4P-001

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Start: Dec 2016Est. completion: Jun 20228 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.